In a nutshell This study examined the link between circulating tumor cells (CTCs) and treatment outcome in metastatic castration-resistant prostate cancer (mCRPC). Authors reported better survival outcomes for mCRPC patients with a significant decline in CTC count during treatment. Some background Metastatic castration-resistant prostate...
Read More
In a nutshell This study examined the benefit of combining radiation therapy with androgen deprivation therapy (ADT) in older men and in men with aggressive cancer cells. Researchers reported reduced mortality risks with combination therapy in all groups studied. Some background Radiation therapy is a common treatment for localized...
Read More
In a nutshell This study examined the benefit of adding apalutamide (JNJ 56021927) to standard hormone therapy in men with castration-resistant prostate cancer (CRPC). Researchers reported preliminary evidence for apalutamide as a safe and effective additional hormone therapy for high-risk CRPC. Some background Hormone therapy is the standard of...
Read More
In a nutshell This study examined robotic assisted radical prostatectomy (RARP) in the treatment of high-risk localized prostate cancer. Researchers reported that the number of risk factors did not increase the risk of cancer recurrence after RARP. Some background Prostate surgery (also called radical prostatectomy) is a common treatment for...
Read More
In a nutshell This study evaluated the impact of different durations of post-surgery chemotherapy in the treatment of locally advanced (spread to the lymph nodes) rectal cancer patients. Researchers suggested that longer post-surgery chemotherapy for stage 3 patients was associated with lower metastasis (spread to other parts of the body) rates and...
Read More
In a nutshell This study tested the efficiency of allocating cancer treatments to elderly non-small cell lung cancer patients based on comprehensive geriatric assessment (CGA). The authors concluded that allocating cancer treatment based on CGA had no difference than current standard allocation methods. Some background In elderly patients with...
Read More
In a nutshell This study investigated the impact of metabolic syndrome on treatment outcome with abiraterone acetate (Zytiga) for hormone-resistant prostate cancer. Researchers concluded that metabolic syndrome has an adverse outcome on disease progression in advanced prostate cancer. Some background Hormone therapy is a common treatment used in...
Read More
In a nutshell This study investigated the efficacy of necitumumab (Portrazza) and chemotherapy combined treatment for locally advanced (spread to the lymph nodes) or metastatic (spread to other areas of the body) colorectal cancer. Researchers suggested that this combination was effective in patients who had not previously been treated, with...
Read More
In a nutshell This study investigated the safety and effectiveness of high-intensity focused ultrasound (HIFU) in treating localized prostate cancer. Researchers concluded that HIFU is an effective treatment option, particularly for men not suitable for surgery or radiation therapy. Some background Localized prostate cancer is cancer that is...
Read More
In a nutshell This study investigated the appropriate waiting time to surgery after radiation and chemotherapy in rectal cancer patients. Researchers suggested that 56 days is the optimal waiting time for surgery after completion of radiation or chemotherapy. Some background Chemotherapy and radiation prior to surgery to remove rectal cancer has...
Read More
In a nutshell The authors evaluated the effectiveness of administering melphalan (Alkeran) and TNF (a protein involved in inflammation process) by ‘isolated limb perfusion (ILP)’- a technique to apply drugs at the sites of tumors in melanoma. They found out that ILP with melphalan and TNF was effective in relieving pain in advanced...
Read More
In a nutshell The authors evaluated the effectiveness of combination therapy of dabrafenib (Tafinlar) and trametinib (Mekinist) in advanced melanoma patients with mutations (permanent changes) in BRAF genes. The authors found out that the combination therapy improved overall survival (time from treatment until death from any cause). Some background...
Read More
